Company

Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a rare, debilitating disease affecting children and young adults. Dynacure’s Dyn101 development program is based on the modulation of the expression of the Dynamin 2 protein, through the use of an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals, the leading biopharmaceutical company in RNA-targeted drug discovery.

2016

Dynacure was founded as a spin-off from the IGBMC (Institute of Genetic and Molecular and Cellular Biology – Unistra/INSERM/CNRS) of Strasbourg.

2017

Dynacure starts co-developing its lead program, DYN101, a generation 2.5 antisense medicine targeting dynamin 2 for the treatment of CNM, with Ionis Pharmaceuticals, the leader in RNA-targeted drug discovery.

2018

Dynacure secures €47 M in financing from key investors and builds out management and clinical teams.
R

2019

Dynacure receives CTA approval to begin Phase 1 / 2 Study “Unite-CNM” for DYN101.

2016

Dynacure was founded as a spin-off from the IGBMC (Institute of Genetic and Molecular and Cellular Biology – Unistra/INSERM/CNRS) of Strasbourg.

2017

Dynacure starts co-developing its lead program, DYN101, a generation 2.5 antisense medicine targeting dynamin 2 for the treatment of CNM, with Ionis Pharmaceuticals, the leader in RNA-targeted drug discovery.

2018

Dynacure secures €47 M in financing from key investors and builds out management and clinical teams
R

2019

Dynacure receives CTA approval to begin Phase 1 / 2 Study “Unite-CNM” for DYN101.